The issue of determining fair value of donated pharmaceuticals has been quiet for a little while. I’ve not seen much discussion of mebendazole on the ‘net lately. Perhaps it is safe to venture back into the waters.
I’d like to mention some of the accounting guidance that is around and provide a few comments.
The AICPA’s 2011 Not-for-Profit Entities Industry Developments Audit Risk Alert contains a two-page discussion of valuing gifts-in-kind (GIK). SOme key paragraphs are quoted below along with my comments.
This is not an exhaustive discussion of the issue and is not a position paper.
This is intended to further the conversation on valuing GIKs, especially for people who don’t keep copies of the audit risk alerts on their nightstand for leisure reading. (You may now roll your eyes in pity for those of us who enjoy reading such things.)